NO985636L - aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier - Google Patents

aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier

Info

Publication number
NO985636L
NO985636L NO985636A NO985636A NO985636L NO 985636 L NO985636 L NO 985636L NO 985636 A NO985636 A NO 985636A NO 985636 A NO985636 A NO 985636A NO 985636 L NO985636 L NO 985636L
Authority
NO
Norway
Prior art keywords
apl
conjugates
methods
treating
antibody
Prior art date
Application number
NO985636A
Other languages
English (en)
Norwegian (no)
Other versions
NO985636D0 (no
Inventor
Edward Jess Victoria
David Matthew Marquis
David S Jones
Lin Yu
Original Assignee
Jolla Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/660,092 external-priority patent/US6207160B1/en
Application filed by Jolla Pharma filed Critical Jolla Pharma
Publication of NO985636D0 publication Critical patent/NO985636D0/no
Publication of NO985636L publication Critical patent/NO985636L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
NO985636A 1996-06-06 1998-12-03 aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier NO985636L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/660,092 US6207160B1 (en) 1995-06-07 1996-06-06 aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
US76050896A 1996-12-05 1996-12-05
PCT/US1997/010075 WO1997046251A1 (fr) 1996-06-06 1997-06-06 PEPTIDES IMMUNOREACTIFS PAR RAPPORT AUX aPL, LEURS CONJUGUES ET PROCEDES DE TRAITEMENT DES PATHOLOGIES DEPENDANTES DE L'ANTICORPS aPL

Publications (2)

Publication Number Publication Date
NO985636D0 NO985636D0 (no) 1998-12-03
NO985636L true NO985636L (no) 1999-02-08

Family

ID=27097975

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985636A NO985636L (no) 1996-06-06 1998-12-03 aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier

Country Status (7)

Country Link
EP (1) EP0954531A1 (fr)
JP (1) JP2000512981A (fr)
KR (1) KR20000016414A (fr)
AU (1) AU734638B2 (fr)
CA (1) CA2256449A1 (fr)
NO (1) NO985636L (fr)
WO (1) WO1997046251A1 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
WO2000006717A2 (fr) 1998-07-27 2000-02-10 Genentech, Inc. Efficacite de transformation amelioree de l'expression a la surface des phages par modification d'une proteine de coque
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
GB9919452D0 (en) * 1999-08-17 1999-10-20 Osteometer Biotech As Specific autoimmune reactions against isomerised/optically inverted epitopes:application for diagnosis of autoimmune diseases
WO2001032858A1 (fr) * 1999-11-05 2001-05-10 Novozymes A/S Procede de criblage a haut debit (hts)
CA2391944A1 (fr) 1999-11-28 2001-06-14 Lajolla Pharmaceutical Company Procedes de traitement de lupus sur la base de l'affinite aux anticorps et procedes de criblage et compositions associees
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002002641A1 (fr) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
WO2002016412A2 (fr) 2000-08-18 2002-02-28 Dyax Corp. Polypeptides de liaison pour proteine stimulatrice des lymphocytes b (blys)
AU2002250032B2 (en) 2001-02-09 2008-06-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633413C (fr) 2001-06-20 2012-08-21 Genentech, Inc. Compositions et procedes destines au diagnostic et au traitement de tumeurs
CN100334228C (zh) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
ATE516042T1 (de) 2001-09-18 2011-07-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
EP2067472A1 (fr) 2002-01-02 2009-06-10 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic d'une tumeur
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20050052467A (ko) 2002-08-12 2005-06-02 다이나박스 테크놀로지 코퍼레이션 면역조절 조성물, 이의 제조방법 및 이의 이용방법
KR100835786B1 (ko) 2003-07-08 2008-06-09 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
CA2747871C (fr) 2003-11-17 2018-04-10 Genentech, Inc. Compositions et methodes de traitement d'une tumeur d'origine hematopoietique
PL1794174T3 (pl) 2004-09-01 2012-11-30 Dynavax Tech Corp Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
ZA200707490B (en) 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
EP2614839A3 (fr) 2006-04-05 2015-01-28 Genentech, Inc. Méthode d'utilisation du BOC/CDO pour moduler l'émission des signaux du hedgehog
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
EP2061904A2 (fr) 2006-09-06 2009-05-27 Ortho-McNeil Pharmaceutical, Inc. Biomarqueurs pour l'évaluation d'une réponse au traitement de c-met
EP2083017A4 (fr) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd Anticorps présentant une activité adcc accrue et son procédé de production
BRPI0807635A2 (pt) 2007-02-22 2014-06-03 Genentech Inc Métodos para detecção de doença inflamatória intestinal
WO2009055076A2 (fr) 2007-10-26 2009-04-30 Dynavax Technologies Corporation Procédés et compositions pour inhiber les réponses immunitaires et l'auto-immunité
EP2304439A4 (fr) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anticorps anti-phospho-akt
WO2009154025A1 (fr) 2008-06-20 2009-12-23 国立大学法人岡山大学 ANTICORPS CONTRE UN COMPLEXE LDL/β2GPI OXYDÉ ET SON UTILISATION
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
KR20120105446A (ko) 2009-10-22 2012-09-25 제넨테크, 인크. 대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
NZ599707A (en) 2009-11-30 2014-07-25 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
WO2011106297A2 (fr) 2010-02-23 2011-09-01 Genentech, Inc. Compositions et méthodes pour le diagnostic et le traitement d'une tumeur
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
BR112012032240A2 (pt) 2010-06-16 2019-09-24 Dynavax Technologies Corporation método de tratamento utilizando inibidores tlr7 e/ou tlr9
ES2703499T3 (es) * 2010-12-22 2019-03-11 Salk Inst Biological Studies Péptidos antagonistas de CRF cíclicos
WO2012129347A1 (fr) 2011-03-21 2012-09-27 Biodesy, Llc Classification d'inhibiteurs de kinase à l'aide de techniques optiques non linéaires
CN103930781A (zh) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 促进分化的方法
EP2766000A2 (fr) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Procédés d'utilisation d'antagonistes de scd1
KR20140119114A (ko) 2012-01-18 2014-10-08 제넨테크, 인크. Fgf19 조절제의 사용 방법
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
CN104168898A (zh) 2012-03-16 2014-11-26 霍夫曼-拉罗奇有限公司 以pak1抑制剂治疗黑色素瘤的方法
WO2013137920A1 (fr) 2012-03-16 2013-09-19 Genentech, Inc. Protéines synthétiques stabilisées du point de vue conformationnel
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
JP6302460B2 (ja) 2012-04-25 2018-03-28 バイオデシー， インコーポレイテッド タンパク質のアロステリックモジュレーターを検出するための方法
WO2013170191A1 (fr) 2012-05-11 2013-11-14 Genentech, Inc. Procédés d'utilisation d'antagonistes de biosynthèse de nicotinamide adénine dinucléotide à partir de nicotinamide
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
SG10201701380TA (en) 2013-03-15 2017-04-27 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2015116902A1 (fr) 2014-01-31 2015-08-06 Genentech, Inc. Récepteurs couplés aux protéines g dans la signalisation hedgehog
WO2015179835A2 (fr) 2014-05-23 2015-11-26 Genentech, Inc. Biomarqueurs mit et leurs méthodes d'utilisation
CN106573961B (zh) 2014-06-20 2022-01-04 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
EP3237906B8 (fr) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Fixation de protéines à des interfaces destinées à être utilisées en détection optique non linéaire
JP6952605B2 (ja) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド 多特異性抗原結合タンパク質
CN110198729A (zh) 2016-09-09 2019-09-03 豪夫迈·罗氏有限公司 卷曲蛋白的选择性肽抑制剂
WO2018152496A1 (fr) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions et méthodes de diagnostic et de traitement de l'infection par le virus zika
EP4230649A3 (fr) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Anticorps et procédés de diagnostic et de traitement d'infection par le virus d'epstein barr
WO2019018629A1 (fr) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Anticorps et procédés de diagnostic et de traitement d'infection par le virus de l'hépatite b
KR20220005568A (ko) 2019-05-09 2022-01-13 제넨테크, 인크. 항체의 제조 방법
CN112480209B (zh) * 2020-11-16 2022-03-04 昆明学院 一种抗皮肤光损伤保护活性多肽rl-pl9及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69028513T2 (de) * 1989-10-19 1997-02-06 Yamasa Shoyu K.K., Choshi, Chiba Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
ES2079653T3 (es) * 1990-04-06 1996-01-16 Yamasa Shoyu Kk Metodos para determinar anticuerpos antifosfolipidos.
EP0523035B1 (fr) * 1990-04-10 1994-10-12 Masur, Walter Processus de fonctionnement d'une thermopompe a compression et thermopompe a compression
EP0642798B1 (fr) * 1993-09-08 2007-04-18 La Jolla Pharmaceutical Company Molécules "platform" définis et de valence non-polymérique et leur conjugés
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies

Also Published As

Publication number Publication date
AU3640497A (en) 1998-01-05
EP0954531A1 (fr) 1999-11-10
WO1997046251A1 (fr) 1997-12-11
KR20000016414A (ko) 2000-03-25
AU734638B2 (en) 2001-06-21
CA2256449A1 (fr) 1997-12-11
EP0954531A4 (fr) 1999-08-31
JP2000512981A (ja) 2000-10-03
NO985636D0 (no) 1998-12-03

Similar Documents

Publication Publication Date Title
NO985636L (no) aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier
EP0833648A4 (fr) PEPTIDES A IMMUNOREACTION aPL, LEURS CONJUGUES, ET METHODES DE TRAITEMENT DES PATHOLOGIES INDUITES PAR LES ANTICORPS aPL
DE69730043D1 (de) Implantierbare eletrodenleitung
HUP0003401A3 (en) Improved methods for processing activated protein c
ZA9811593B (en) Substantially pure histidine-linked protein polymer conjugates
ZA986072B (en) Adsorption apparatus and methods.
DE69725567D1 (de) Haltetransplantat
ZA97631B (en) Migraine treatment.
IL118969A0 (en) Purse string suture apparatus
EP0911397A4 (fr) Proteines d'antigenes tumoraux, genes derives de ces proteines, et peptides d'antigenes tumoraux
EP0904539A4 (fr) Inhibition d'interactions entre proteines
GB9607129D0 (en) Uv dryer with improved reflector
GB9606126D0 (en) Biosensors
ZA973211B (en) Support post.
IL117674A0 (en) UV reflector
GB2318340B (en) Envelope closing apparatus
ZA968185B (en) Protein.
ZA989574B (en) Indole derivative useful in therapy.
TR199600586A3 (tr) Ürün ve hizmetlerin karsiliginin ödenmesi için proses.
KR970052847U (ko) 시트 제품 적재 장치
EP0915100A4 (fr) Nouvelle proteine
GB9607130D0 (en) Uv dryers
ZA968224B (en) Hair-styling apparatus.
BR9705072A (pt) Aparelho de difusão
AU787P (en) APRIL GLO Prunus persica var. nucipersica

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application